Jacqualyn A. Fouse, Ph.D., known as Jacki, is a seasoned leader in biotechnology, having served as the CEO of Agios Pharmaceuticals from early 2019 until August 2022. She holds a Ph.D. in Biochemistry from the University of Illinois at Urbana-Champaign,...

Jacqualyn A. Fouse, Ph.D., known as Jacki, is a seasoned leader in biotechnology, having served as the CEO of Agios Pharmaceuticals from early 2019 until August 2022. She holds a Ph.D. in Biochemistry from the University of Illinois at Urbana-Champaign, and her career includes significant executive roles at companies like Celgene Corporation, Dermavant Sciences, and Bunge Limited. Jacki’s approach is practical, focused on aligning operations with company goals, especially in product development and commercialization. During her time at Agios, she drove the company towards crucial milestones in critical areas such as hematology and oncology. Interesting to note, her total compensation peaked at over $6.5 million in 2021, reflecting the competitive nature of the biotechnology industry. In addition to her executive roles, she has also served on the boards of Incyte Corporation and Dick’s Sporting Goods, showcasing her influence across multiple sectors. Despite stepping down as CEO, she continues to shape the future of Agios as the Chair of the Board, emphasizing her ongoing commitment to the company.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Agios Pharmaceuticals CEOs

A

Jacqualyn A. Fouse, Ph.D.

Ex-CEO of Agios Pharmaceuticals

Education

Ph.D. in Biochemistry from the University of Illinois at Urbana-Champaign

Field of Expertise

Healthcare & Life Sciences - Biotechnology

Sector of Economy

Healthcare

Born

May 14, 1963 - 62 years ago

CEO of Agios Pharmaceuticals for

3 years 4 months (Mar 2019 - Aug 2022)

Previous Experience

Various leadership roles in the pharmaceutical and biotechnology sectors, including positions at Celgene Corporation and ImmunoGen, Inc.

Rivals

Competitors/colleagues of Jacqualyn A. Fouse, Ph.D.

Holdings

See how much did Jacqualyn A. Fouse, Ph.D. make over time.

During her tenure, Dr. Fouse held significant equity in Agios Pharmaceuticals. At one point, she had over 248,000 unexercised stock options, one of which was granted at an exercise price of $53.87 per share. This could mean a large potential...

During her tenure, Dr. Fouse held significant equity in Agios Pharmaceuticals. At one point, she had over 248,000 unexercised stock options, one of which was granted at an exercise price of $53.87 per share. This could mean a large potential payout if the company performed well. By the end of 2021, she had about 163,000 options remaining, reflecting her stakes in Agios as a drive for success. With stock options tied to the company’s future, these holdings show her commitment to Agios. When she officially left the position of CEO in August 2022, her unvested equity awards were set to continue vesting, keeping her financially engaged with the company's path forward. Her wealth in Agios not only tied her success to the company's but also aligned her interests with those of investors.

Loading...

Total Stock Sold

$968.81K

AGIO

$968.81K

37,622 AGIO shares

What if they kept their stock?

If Jacqualyn A. Fouse, Ph.D. didn't sell their stock, today they would have:
Extra AGIO37,622 shares worth $2.10M.
This is 117.19% and $1.14M more than what they got when they sold the stock.

Insider Trading

See recent insider trades of Jacqualyn A. Fouse, Ph.D..

INCY

2,830 shares

INCY

Jun 12, 2024

Received

AGIO

$214.64K

AGIO at $27.55/share

Apr 8, 2024

Sale

AGIO

$232.02K

AGIO at $21.64/share

Jan 20, 2024

Sale

AGIO

$192.91K

AGIO at $22.99/share

Jan 5, 2024

Sale

AGIO

$303.96K

AGIO at $28.36/share

Jun 28, 2023

Sale

INCY

2,505 shares

INCY

Jun 14, 2023

Received

INCY

$20.24K

INCY at $80.32/share

Dec 30, 2022

Received

INCY

$19.39K

INCY at $66.64/share

Sep 30, 2022

Received

INCY

$20.89K

INCY at $75.97/share

Jun 30, 2022

Received

INCY

2,144 shares

INCY

Jun 15, 2022

Received

Compensation History

See how much did Jacqualyn A. Fouse, Ph.D. make over time.

Dr. Fouse's compensation varied during her time at Agios. In 2020, she earned about $1.25 million in total, including a performance bonus. By 2021, this figure jumped to around $6.5 million, emphasizing a significant increase during her leadership, likely due to performance metrics being met. No bonuses were awarded in 2022 as she resigned in August, evidencing how performance and timing affect compensation directly. Her compensation package was aligned with performance metrics, ensuring she was rewarded for the company’s achievements and strategic goals. The package included salary, stock options, and various benefits which reinforced her direction and the overall success of Agios.

Year

2022

Total Compensation

$1.20M

Salary

$466.76K

Board Justification

The compensation philosophy is designed to attract and retain superior executive talent while aligning the interests of executives with those of stockholders through performance-based incentives.

Bonus

$0.00

Board Justification

No bonus was awarded for the year 2022 as Dr. Fouse resigned as CEO effective August 8, 2022.

Other

$10.31K

Board Justification

This includes a matching contribution under the company’s 401(k) plan and the dollar value of company-paid life insurance and disability insurance premiums paid during the fiscal year.

Restricted Stock

$719.28K(0 RSU)

Board Justification

No stock was vested in 2022 as the focus is on stock grants and options that are not vested.

Performance Metrics

Performance metrics for determining compensation included achieving specific corporate goals related to product development and commercialization.

Other Agios Pharmaceuticals CEOs

Here are other CEOs of Agios Pharmaceuticals

Brian Goff

CEO of Agios Pharmaceuticals

August 2022 - Present